Cheek cells could reverse blindness from rare eye condition
NCT ID NCT03949881
First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This study tests a new treatment for people who are blind due to a rare condition where both eyes lack stem cells needed to keep the cornea clear. Doctors take a small sample of cells from the inside of the cheek, grow them into a thin sheet in the lab, and then graft that sheet onto the eye to restore a clear surface. The goal is to improve vision and reduce pain, with 40 adults expected to take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOTAL BILATERAL LIMBAL CELL DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ophthalmology department, Edouard Herriot hospital, Hospices Civils de Lyon
RECRUITINGLyon, 69003, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.